Industry
Generics and Biosimilars market research
Market entry and tender research for generics and biosimilars.
HealthcareMarketResearch runs generics and biosimilars market research for global leaders, challengers and investors. Our 5,000+ researchers include practising clinicians, procurement leaders, payers and former executives from the generics and biosimilars industry.
Studies combine expert calls, qualitative interviews and quantitative surveys, so you can size the opportunity, understand stakeholders and plan go-to-market with confidence.
Topics we research
- Tender dynamics
- Pharmacy substitution
- Pricing erosion
- Physician confidence
Relevant services
At a glance
Generics and Biosimilars market research at a glance
The audiences, methods and timelines a typical generics and biosimilars study runs on.
- Audiences
- Generics and Biosimilars specialists and clinicians, pharmacy and procurement leads, payers and HTA assessors, plus former industry executives
- Typical methods
- Expert calls, in-depth interviews, online surveys, advisory boards and competitive intelligence
- Research focus
- tender dynamics · pharmacy substitution · pricing erosion · physician confidence
- Geography
- 100+ Indian cities, metro and tier 2, plus global peer benchmarks
- Expert matching
- 24–48 hours from a confirmed brief
- Fieldwork window
- 5–10 business days for most interview and survey studies
- Core outputs
- Screened respondent profiles, recordings and transcripts, coded data tables and a generics and biosimilars readout with implications
- Regulatory context
- Studies are designed with CDSCO, FDA and EMA requirements in mind, and run under the pharmaceutical market research codes.
Scope, sample and timings are confirmed in writing before fieldwork starts.
Why teams commission it
Decisions generics and biosimilars research supports
Each brief starts from the decision it has to inform, so the readout answers the question your team is actually facing.
Where to compete
Which generics and biosimilars segments, indications and accounts justify investment, and how tender dynamics changes that picture.
What to build
Which features, claims and configurations stakeholders genuinely value, pressure-tested against pharmacy substitution.
What it can be priced at
What buyers and payers will fund, the evidence they ask for first, and how pricing erosion shapes willingness to pay.
How to launch
Sequencing, channel and messaging choices, grounded in how physician confidence works in day-to-day practice.
Who to partner with
How potential partners, distributors and referral sources read your proposition in generics and biosimilars.
Where the risk sits
Competitive moves, switching triggers and the objections most likely to stall generics and biosimilars adoption.
Stakeholders
Who we reach in generics and biosimilars
We recruit the people who make and influence the decision — not only the easiest audience to find. Every expert is screened for recency of practice and conflicts of interest.
Clinical and scientific
- Practising specialists and consultants
- Clinical investigators and trial site staff
- Hospital and specialty pharmacists
- Nurses and allied health professionals
Generics and Biosimilars commercial teams
- Brand, portfolio and marketing leads
- Market access, pricing and HEOR leads
- Business development and licensing leads
- Medical affairs and MSL teams
Buyers, payers and influencers
- Procurement and category managers
- Payer medical directors and HTA assessors
- Distributors, wholesalers and channel partners
- Patients, carers and advocacy group leads
How it runs
A generics and biosimilars research programme, stage by stage
Senior researchers at our Pune, Maharashtra, India headquarters design, moderate and analyse every study.
- 01
Brief and research design
We turn your generics and biosimilars question into a screener, discussion guide or questionnaire, and agree the decision the readout has to support.
Scoped in writing
- 02
Recruit and screen
We identify generics and biosimilars stakeholders from our 5,000+ network, then screen for recency of practice, relevance and conflicts before anything is booked.
24–48 hours
- 03
Fieldwork
Expert calls, in-depth interviews or surveys run with senior moderation, covering tender dynamics and the rest of your question set.
5–10 business days
- 04
Analysis and readout
Findings are coded, triangulated across audiences and delivered as a decision-ready report, with a live debrief for your team.
Report and debrief
Compliance
Standards every generics and biosimilars study runs under
Compliance is designed into the screener and the guide, not bolted on at the end.
Research codes
generics and biosimilars guides follow EphMRA, BHBIA and Insights Association standards, including adverse event and off-label handling.
Regulatory framing
Studies are designed with CDSCO, FDA and EMA requirements in mind, and run under the pharmaceutical market research codes.
Data protection
Recruitment, transcripts and data files are handled under GDPR, HIPAA and India's DPDP Act, with pseudonymised outputs.
Conflict screening
Every expert is screened for employer restrictions, confidentiality obligations and conflicts of interest before a session is confirmed.
FAQs
Generics and Biosimilars market research questions
What is generics and biosimilars market research?+
generics and biosimilars market research is primary research with the clinicians, buyers, payers and executives who shape the generics and biosimilars market. HealthcareMarketResearch covers tender dynamics, pharmacy substitution, pricing erosion, physician confidence through expert calls, in-depth interviews, surveys and advisory boards.
Who do you interview for generics and biosimilars studies?+
We recruit from a network of 5,000+ market researchers, KOLs and healthcare experts. For generics and biosimilars that typically means practising specialists, hospital pharmacists, procurement and value analysis leads, payers and former industry executives, all screened for recency and conflicts.
How quickly can a generics and biosimilars project start?+
Expert calls usually start within 24–48 hours of a confirmed brief. Surveys and qualitative studies typically go to field in 5–10 business days, depending on audience and sample size.
Which generics and biosimilars questions can you answer?+
Market entry and tender research for generics and biosimilars. Common briefs cover tender dynamics, pharmacy substitution, pricing erosion, physician confidence, along with competitor positioning, pricing expectations and launch readiness.
Is your generics and biosimilars research compliant?+
Yes. Studies follow EphMRA, BHBIA and Insights Association guidelines, with adverse event reporting and off-label rules written into every guide. Studies are designed with CDSCO, FDA and EMA requirements in mind, and run under the pharmaceutical market research codes.
Coverage
Where we run generics and biosimilars research in India
Studies are designed and analysed at our Pune, Maharashtra, India headquarters, with recruitment and fieldwork across 100+ Indian cities — metro, tier 2 and tier 3.
All industries
Explore the other 24 healthcare segments
Grouped by the kind of organisation or therapy area you work in, so you can find the neighbouring page quickly.
Life sciences companies
Therapy areas
Care delivery, payers and technology
Have a healthcare question that needs real answers?
Brief us today and talk to a verified expert this week.